Roy O Mathew, Sadiya S Khan, Katherine R Tuttle, Jennifer E Ho, Dmitry Abramov, Sripal Bangalore, Mandeep S Sidhu, Chiadi E Ndumele, Tiffany M Powell-Wiley, Ian J Neeland, Josef Coresh, Mitchell S V Elkind, Janani Rangaswami
{"title":"Performance of the American Heart Association's PREVENT risk score for cardiovascular risk prediction in a multiethnic population.","authors":"Roy O Mathew, Sadiya S Khan, Katherine R Tuttle, Jennifer E Ho, Dmitry Abramov, Sripal Bangalore, Mandeep S Sidhu, Chiadi E Ndumele, Tiffany M Powell-Wiley, Ian J Neeland, Josef Coresh, Mitchell S V Elkind, Janani Rangaswami","doi":"10.1038/s41591-025-03789-2","DOIUrl":null,"url":null,"abstract":"<p><p>The Predicting Risk of Cardiovascular EVENTS (PREVENT) equations, created and endorsed by the American Heart Association, provide cardiovascular risk estimates for the general population, but have not yet been tested in multiethnic populations. In the present study, in a large nationwide multiethnic sample of US veterans, the utility of PREVENT to predict the risk of total cardiovascular disease (CVD: fatal and nonfatal myocardial infarction, stroke or heart failure; PREVENT-CVD), atherosclerotic cardiovascular disease (ASCVD: fatal and nonfatal myocardial infarction or stroke; PREVENT ASCVD) and heart failure was evaluated. We assessed the discrimination and calibration performance of ASCVD prediction with PREVENT ASCVD compared with a previous risk-prediction score, pooled cohort equations (PCEs). Among 2,500,291 veterans aged 30-79 years (93.9% men and 6.1% women), 407,342 total CVD events occurred over a median (interquartile range (IQR)) follow-up of 5.8 (IQR = 3.1-8.3) years. The Concordance index (C-index) (95% confidence interval (CI)) for PREVENT-CVD was 0.65 (95% CI = 0.65-0.65) in the overall sample and was similar across different race and ethnic groups (Asian, Native Hawaiian or Pacific Islander, 0.70 (95% CI = 0.69-0.71); Hispanic, 0.70 (95% CI = 0.69-0.70); non-Hispanic Black. 0.68 (95% CI = 0.68-0.69) and non-Hispanic White, 0.65 (95% CI = 0.64-0.65)). C-indices were similar between PREVENT ASCVD and PCEs and ranged from 0.61 to 0.63. Calibration slopes for PREVENT-CVD and -ASCVD in the overall sample were 1.09 (s.e. = 0.04) and 1.15 (s.e. = 0.04), respectively. In contrast, PCEs demonstrated overprediction for ASCVD with a calibration slope of 0.51 (s.e. = 0.06). Calibration slopes for PREVENT and PCEs were similar across race and ethnic groups. Among US veterans, the PREVENT equations accurately estimated CVD and ASCVD risk with some variability across race and ethnicity groups and outperformed PCEs for ASCVD risk prediction.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03789-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The Predicting Risk of Cardiovascular EVENTS (PREVENT) equations, created and endorsed by the American Heart Association, provide cardiovascular risk estimates for the general population, but have not yet been tested in multiethnic populations. In the present study, in a large nationwide multiethnic sample of US veterans, the utility of PREVENT to predict the risk of total cardiovascular disease (CVD: fatal and nonfatal myocardial infarction, stroke or heart failure; PREVENT-CVD), atherosclerotic cardiovascular disease (ASCVD: fatal and nonfatal myocardial infarction or stroke; PREVENT ASCVD) and heart failure was evaluated. We assessed the discrimination and calibration performance of ASCVD prediction with PREVENT ASCVD compared with a previous risk-prediction score, pooled cohort equations (PCEs). Among 2,500,291 veterans aged 30-79 years (93.9% men and 6.1% women), 407,342 total CVD events occurred over a median (interquartile range (IQR)) follow-up of 5.8 (IQR = 3.1-8.3) years. The Concordance index (C-index) (95% confidence interval (CI)) for PREVENT-CVD was 0.65 (95% CI = 0.65-0.65) in the overall sample and was similar across different race and ethnic groups (Asian, Native Hawaiian or Pacific Islander, 0.70 (95% CI = 0.69-0.71); Hispanic, 0.70 (95% CI = 0.69-0.70); non-Hispanic Black. 0.68 (95% CI = 0.68-0.69) and non-Hispanic White, 0.65 (95% CI = 0.64-0.65)). C-indices were similar between PREVENT ASCVD and PCEs and ranged from 0.61 to 0.63. Calibration slopes for PREVENT-CVD and -ASCVD in the overall sample were 1.09 (s.e. = 0.04) and 1.15 (s.e. = 0.04), respectively. In contrast, PCEs demonstrated overprediction for ASCVD with a calibration slope of 0.51 (s.e. = 0.06). Calibration slopes for PREVENT and PCEs were similar across race and ethnic groups. Among US veterans, the PREVENT equations accurately estimated CVD and ASCVD risk with some variability across race and ethnicity groups and outperformed PCEs for ASCVD risk prediction.
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.